Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series

J Neuroimmunol. 2022 Sep 15:370:577933. doi: 10.1016/j.jneuroim.2022.577933. Epub 2022 Jul 14.

Abstract

This case series describes 9 patients diagnosed with myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorder (MOGAD) following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients developed neurological symptoms between 4 days and 5 weeks following SARS-CoV-2 infection. Myelitis was observed in 4 patients; 4 presented with optic neuritis; and encephalopathy was observed in 3. Serum MOG-IgG cell-based assay was medium or high positive in each case. The majority of patients had near-complete recovery following acute immunosuppression. This series adds to the growing number of cases of central nervous system demyelination following SARS-CoV-2 infection and highlights a potential role of infection in the immunopathogenesis of MOGAD.

Keywords: COVID-19; MOGAD; Optic neuritis; SARS-CoV-2; Transverse myelitis.

MeSH terms

  • Autoantibodies
  • COVID-19* / complications
  • Humans
  • Immunoglobulin G
  • Myelin-Oligodendrocyte Glycoprotein
  • Neuromyelitis Optica*
  • SARS-CoV-2

Substances

  • Autoantibodies
  • Immunoglobulin G
  • Myelin-Oligodendrocyte Glycoprotein